Back to Browse Journals » Vascular Health and Risk Management » Volume 3 » Issue 6

A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications

Authors Behzad Molavi, Negah Rassouli, Suveer Bagwe, Neda Rasouli

Published 15 January 2008 Volume 2007:3(6) Pages 967—973

Behzad Molavi1, Negah Rassouli2, Suveer Bagwe1, Neda Rasouli2

Central Arkansas Veterans Healthcare System and University of Arkansas for Medical sciences, 1Division of cardiology and 2Division of Endocrinology, College of Medicine, Little Rock, Arkansas, USA

Abstract: The rising incidence of obesity and insulin resistance to epidemic proportions has closely paralleled the surge in the prevalence of diabetes and outpaced therapeutic advances in diabetes prevention and treatment. Current evidence points to obesity induced oxidative stress and chronic inflammation as the common denominators in the evolution of insulin resistance and diabetes. Of all the hypoglycemic agents in the pharmacological arsenal against diabetes, thiazolidinediones, in particular pioglitazone, as well as metformin appear to have additional effects in ameliorating oxidative stress and inflammation; rendering them attractive tools for prevention of insulin resistance and diabetes. In addition to their hypoglycemic and lipid modifying properties, pioglitazone and metformin have been shown to exert anti-oxidative and anti-inflammatory effects in vascular beds, potentially slowing the accelerated atherosclerosis in diabetes, which is the major cause of morbidity and mortality in the affected population. The combination of pioglitazone and metformin would thus appear to be an effective pharmacological intervention in prevention and treatment of diabetes. Finally, this review will address the currently available evidence on diabetic cardiomyopathy and the potential role of combination therapy with pioglitazone and metformin.

Keywords: insulin resistance, oxidative stress, inflammation, pioglitazone, metformin, atherosclerosis, diabetic cardiomyopathy

Download Article [PDF] 

Readers of this article also read:

Synthesis, pharmacokinetics, and biological use of lysine-modified single-walled carbon nanotubes [Erratum]

Mulvey JJ, Feinberg EN, Alidori S, McDevitt MR, Heller DA, Scheinberg DA

International Journal of Nanomedicine 2015, 10:595-596

Published Date: 14 January 2015

Activation of Schwann cells in vitro by magnetic nanocomposites via applied magnetic field

Liu Z, Huang L, Liu L, Luo B, Liang M, Sun Z, Zhu S, Quan X, Yang Y, Ma T, Huang J, Luo Z

International Journal of Nanomedicine 2015, 10:43-61

Published Date: 17 December 2014

Short-term effect of the HMG-CoA reductase inhibitor rosuvastatin on erythrocyte nitric oxide synthase activity

Barbara Ludolph, Wilhelm Bloch, Malte Kelm, Rainer Schulz, Petra Kleinbongard

Vascular Health and Risk Management 2007, 3:1069-1073

Published Date: 15 January 2008

Inhaled insulin for controlling blood glucose in patients with diabetes

Bernard L Silverman, Christopher J Barnes, Barbara N Campaigne, Douglas B Muchmore

Vascular Health and Risk Management 2007, 3:947-958

Published Date: 15 January 2008

Review of sitagliptin phosphate: a novel treatment for type 2 diabetes

Baptist Gallwitz

Vascular Health and Risk Management 2007, 3:203-210

Published Date: 15 May 2007

Metabolic syndrome: the danger signal in atherosclerosis

Patrick Mathieu, Philippe Pibarot, Jean-Pierre Després

Vascular Health and Risk Management 2006, 2:285-302

Published Date: 15 September 2006